LILRB2/CD85d/ILT4[Biotin], His & Avi, Human
LILRB2/CD85d/ILT4[Biotin], His & Avi, Human

Immobilized LILRB2/CD85d/ILT4[Biotin], His & Avi, Human, His Tag at 0.5 μg/ml (100 μl/Well) on streptavidin(5 μg/ml) precoated plate. Dose response curve for Anti-LILRB2 Antibody, hFc Tag with the EC50 of 4.0ng/ml determined by ELISA.

LILRB2/CD85d/ILT4[Biotin], His & Avi, Human

The purity of LILRB2/CD85d/ILT4[Biotin], His & Avi, Human is greater than 95% as determined by SEC-HPLC.

LILRB2/CD85d/ILT4[Biotin], His & Avi, Human

LILRB2/CD85d/ILT4[Biotin], His & Avi, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

LILRB2/CD85d/ILT4[Biotin], His & Avi, Human

The immunoglobulin-like transcript (ILT) comprise a family of activating and inhibitory type immunoreceptors whose genes are located in the same locus that encodes killer cell Ig-like receptors (KIR). ILT4, also known as LIR-2 and LILRB2, is a type I transmembrane protein expressed primarily on monocytes and dendritic cells (DC). LILRB2 is a receptor for class I MHC antigens. Recognizes a broad spectrum of HLA-A, HLA-B, HLA-C, HLA-G and HLA-F alleles.
Z04542
¥123,118.00

Ask us a question
Product Introduction
Species Human
Protein Construction
LILRB2/CD85d/ILT4 (Gln22-His458)
Accession # Q8N423-1		 His Avi
N-term C-term
Conjugate Biotin
Purity > 95% as determined by Bis­Tris PAGE 
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA.Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 50.2 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 70-75 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles.

Examples
  • LILRB2/CD85d/ILT4[Biotin], His & Avi, Human
    • LILRB2/CD85d/ILT4[Biotin], His & Avi, Human

    Immobilized LILRB2/CD85d/ILT4[Biotin], His & Avi, Human, His Tag at 0.5 μg/ml (100 μl/Well) on streptavidin(5 μg/ml) precoated plate. Dose response curve for Anti-LILRB2 Antibody, hFc Tag with the EC50 of 4.0ng/ml determined by ELISA.

  • LILRB2/CD85d/ILT4[Biotin], His & Avi, Human
    • LILRB2/CD85d/ILT4[Biotin], His & Avi, Human

    The purity of LILRB2/CD85d/ILT4[Biotin], His & Avi, Human is greater than 95% as determined by SEC-HPLC.

  • LILRB2/CD85d/ILT4[Biotin], His & Avi, Human
    • LILRB2/CD85d/ILT4[Biotin], His & Avi, Human

    LILRB2/CD85d/ILT4[Biotin], His & Avi, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.


Background
Target Background The immunoglobulin-like transcript (ILT) comprise a family of activating and inhibitory type immunoreceptors whose genes are located in the same locus that encodes killer cell Ig-like receptors (KIR). ILT4, also known as LIR-2 and LILRB2, is a type I transmembrane protein expressed primarily on monocytes and dendritic cells (DC). LILRB2 is a receptor for class I MHC antigens. Recognizes a broad spectrum of HLA-A, HLA-B, HLA-C, HLA-G and HLA-F alleles.
Synonyms CD85d; ILT4; ILT-4; ILT4CD85d; LILRB2; LIR2; MIR10

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.